RPS-Strategy Redefined - Clinical Trials Asia

Pacra Portal

GCP Navigator
GCP Navigator
GCP Guidelines on your fingertips
Download it now. Click here
Clinical Trial Supply 2017 - Clinical Trials Asia
Outsourcing Clinical Trials 2017 - Clinical Trials Asia

RSS Feed

  • Yet another Teva executive is heading out the door, and at least one analyst has some concerns about his departure.

  • After recently blowing past analyst expectations with its third-quarter results, Perrigo is feeling good enough to look toward some M&A, with its eye on the consumer health business that Germany’s Merck KGaA has put on the auction block.

  • Merck’s Keytruda boasts an FDA approval in third-line stomach cancer, but its ambitions for moving earlier into treatment just took a hit.

  • Amid tough times at the drugmaker, Teva is launching an exclusive generic to Gilead Sciences' hepatitis B and HIV antiviral Viread.

  • For the second straight week, there’s a new psoriatic arthritis drug on the block. This week, that drug is Pfizer’s Xeljanz, which nabbed an FDA approval late Thursday to treat patients who haven’t adequately responded to or are intolerant of methotrexate or other disease-modifying medications.

  • Gilead and its much-hailed CAR-T for lymphoma, Yescarta, have been hit by some bad press over the past few days, with news that only five patients have actually received the potentially lifesaving therapy. Some critics point to its $373,000 price as the problem, but it may be more nuanced than that.

  • As Novartis preps for its upcoming CEO transition, so too will it have to find a new leader in oncology. One of the drugmaker's top executives, Bruno Strigini, is retiring for personal reasons, Novartis announced Friday.

  • Bristol-Myers Squibb forms new immuno-oncology deal with Ono, Eisai's Lenvima wins NICE backing in kidney cancer, Sanofi tries to persuade Philippines lawmakers that Dengvaxia is safe and works to develop a solution for the fallout, and more.

  • With just-arrived competition in mantle cell lymphoma, Johnson & Johnson’s Imbruvica has snagged reimbursement backing in an important new market.

  • Bristol-Myers Squibb could have yet another approval for its Opdivo-plus-Yervoy combo on the way. The FDA has started a priority review on the two-drug combo as a treatment for kidney cancer, based on data released just three months ago.

  • © 2017 PACRA. All Rights Reserved.
    Powered by: Visual Sparks Technologies